A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

HZC102970: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)

Study Overview

• Status: Completed
• Conditions: Pulmonary Disease, Chronic Obstructive
• Intervention / Treatment: Drug: FF/GW642444 Inhalation Powder; Drug: GW642444 Inhalation Powder

• Study Type: Interventional
• Enrollment (Actual): 1635
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Ciudad Autónoma de Buenos Aires, Argentina, C1121ABE
    • GSK Investigational Site
  • Mendoza, Argentina, M5500CCG
    • GSK Investigational Site
  • Tucuman, Argentina, 4000
    • GSK Investigational Site
  • Tucumán, Argentina, T4000DGF
    • GSK Investigational Site
  • Buenos Aires
    • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1405BCH
      • GSK Investigational Site
• Australia
  • New South Wales
    • Kingswood, New South Wales, Australia, 2747
      • GSK Investigational Site
    • Westmead, New South Wales, Australia, 2145
      • GSK Investigational Site
  • Queensland
    • Auchenflower, Queensland, Australia, 4066
      • GSK Investigational Site
    • Southport, Queensland, Australia, 4215
      • GSK Investigational Site
  • South Australia
    • Adelaide, South Australia, Australia, 5000
      • GSK Investigational Site
  • Tasmania
    • Hobart, Tasmania, Australia, 7000
      • GSK Investigational Site
  • Victoria
    • Box Hill, Victoria, Australia, 3128
      • GSK Investigational Site
  • Western Australia
    • Nedlands, Western Australia, Australia, 6009
      • GSK Investigational Site
• Canada
  • Manitoba
    • Winnipeg, Manitoba, Canada, R2K 3S8
      • GSK Investigational Site
  • Nova Scotia
    • Truro, Nova Scotia, Canada, B2N 1L2
      • GSK Investigational Site
  • Ontario
    • Grimsby, Ontario, Canada, L3M 1P3
      • GSK Investigational Site
    • Hamilton, Ontario, Canada, L8M 1K7
      • GSK Investigational Site
    • London, Ontario, Canada, N5W 6A2
      • GSK Investigational Site
    • Newmarket, Ontario, Canada, L3Y 5G8
      • GSK Investigational Site
    • Sarnia, Ontario, Canada, N7T 4X3
      • GSK Investigational Site
    • Toronto, Ontario, Canada, M5G 1N8
      • GSK Investigational Site
  • Quebec
    • Gatineau, Quebec, Canada, J8Y 6S8
      • GSK Investigational Site
    • Mirabel, Quebec, Canada, J7J 2K8
      • GSK Investigational Site
    • Montreal, Quebec, Canada, H2X 2P4
      • GSK Investigational Site
• Chile
  • Talcahuano, Chile, 4270918
    • GSK Investigational Site
  • Región Metro De Santiago
    • Puente Alto - Santiago, Región Metro De Santiago, Chile, 8207257
      • GSK Investigational Site
    • Santiago, Región Metro De Santiago, Chile, 7500691
      • GSK Investigational Site
• Denmark
  • Aalborg, Denmark, 9100
    • GSK Investigational Site
  • Aarhus C, Denmark, 8000
    • GSK Investigational Site
  • Hvidovre, Denmark, 2650
    • GSK Investigational Site
  • Kobenhavn NV, Denmark, 2400
    • GSK Investigational Site
  • Odense C, Denmark, 5000
    • GSK Investigational Site
• Germany
  • Hamburg, Germany, 20354
    • GSK Investigational Site
  • Hessen
    • Frankfurt, Hessen, Germany, 60596
      • GSK Investigational Site
    • Kassel, Hessen, Germany, 34121
      • GSK Investigational Site
    • Marburg, Hessen, Germany, 35037
      • GSK Investigational Site
    • Wiesbaden, Hessen, Germany, 65183
      • GSK Investigational Site
  • Niedersachsen
    • Hannover, Niedersachsen, Germany, 30167
      • GSK Investigational Site
  • Nordrhein-Westfalen
    • Essen, Nordrhein-Westfalen, Germany, 45359
      • GSK Investigational Site
• Italy
  • Campania
    • Salerno, Campania, Italy, 84100
      • GSK Investigational Site
    • San Felice A Cancello Caserta, Campania, Italy, 81027
      • GSK Investigational Site
  • Emilia-Romagna
    • Modena, Emilia-Romagna, Italy, 41124
      • GSK Investigational Site
    • Parma, Emilia-Romagna, Italy, 43100
      • GSK Investigational Site
  • Lazio
    • Roma, Lazio, Italy, 00168
      • GSK Investigational Site
  • Puglia
    • Foggia, Puglia, Italy, 71100
      • GSK Investigational Site
  • Sicilia
    • Palermo, Sicilia, Italy, 90146
      • GSK Investigational Site
  • Toscana
    • Pisa, Toscana, Italy, 56124
      • GSK Investigational Site
  • Umbria
    • Perugia, Umbria, Italy, 06156
      • GSK Investigational Site
• Mexico
  • Jalisco
    • Guadalajara, Jalisco, Mexico, 44600
      • GSK Investigational Site
    • Zapopan, Jalisco, Mexico, 45040
      • GSK Investigational Site
  • Nuevo León
    • Monterrey, Nuevo León, Mexico, 64460
      • GSK Investigational Site
• Netherlands
  • Almelo, Netherlands, 7609 PP
    • GSK Investigational Site
  • Almere, Netherlands, 1315 RA
    • GSK Investigational Site
  • Beek, Netherlands, 6191 JW
    • GSK Investigational Site
  • Breda, Netherlands, 4819 EV
    • GSK Investigational Site
  • Eindhoven, Netherlands, 5623 EJ
    • GSK Investigational Site
  • Groningen, Netherlands, 9728 NP
    • GSK Investigational Site
  • Hoorn, Netherlands, 1624 NP
    • GSK Investigational Site
  • Horn, Netherlands, 6085 NM
    • GSK Investigational Site
  • Nieuwegein, Netherlands, 3435 CM
    • GSK Investigational Site
  • Zutphen, Netherlands, 7207 AE
    • GSK Investigational Site
• Peru
  • Callao, Peru, Callao 2
    • GSK Investigational Site
  • Lima
    • Lima 18, Lima, Peru
      • GSK Investigational Site
    • San Miguel, Lima, Peru, Lima 32
      • GSK Investigational Site
    • Santiago de Surco, Lima, Peru, Lima 33
      • GSK Investigational Site
• South Africa
  • Bellville, South Africa, 7530
    • GSK Investigational Site
  • Bloemfontein, South Africa, 9301
    • GSK Investigational Site
  • Cape Town, South Africa, 7572
    • GSK Investigational Site
  • Gatesville, South Africa, 7764
    • GSK Investigational Site
  • Mowbray, South Africa, 7700
    • GSK Investigational Site
  • Roodepoort, South Africa, 1724
    • GSK Investigational Site
  • Worcester, South Africa, 6850
    • GSK Investigational Site
  • Gauteng
    • Meyerspark, Gauteng, South Africa, 0184
      • GSK Investigational Site
    • Parktown, Gauteng, South Africa, 2193
      • GSK Investigational Site
    • Waterkloof Ridge, Gauteng, South Africa, 0181
      • GSK Investigational Site
• Spain
  • Alicante, Spain, 03114
    • GSK Investigational Site
  • Cartagena (Murcia), Spain, 30202
    • GSK Investigational Site
  • Cáceres, Spain, 10003
    • GSK Investigational Site
  • Elda, Spain, 03600
    • GSK Investigational Site
  • Galdakano, Spain, 48960
    • GSK Investigational Site
  • Madrid, Spain, 28040
    • GSK Investigational Site
  • Orihuela/Alicante, Spain, 03314
    • GSK Investigational Site
  • Pama de Mallorca, Spain, 07010
    • GSK Investigational Site
  • Pozuelo De Alarcón/Madrid, Spain, 28223
    • GSK Investigational Site
• Sweden
  • Bankeryd, Sweden, SE-564 31
    • GSK Investigational Site
  • Karlskrona, Sweden, SE-371 41
    • GSK Investigational Site
  • Lidingö, Sweden, SE-181 58
    • GSK Investigational Site
  • Åtvidaberg, Sweden, SE-597 26
    • GSK Investigational Site
• United Kingdom
  • Cambridge, United Kingdom, CB2 0QQ
    • GSK Investigational Site
  • Chertsey, Surrey, United Kingdom, KT16 0PZ
    • GSK Investigational Site
  • Wythenshawe, Manchester, United Kingdom, M23 9LT
    • GSK Investigational Site
  • Hampshire
    • Southampton, Hampshire, United Kingdom, SO16 6YD
      • GSK Investigational Site
  • Wiltshire
    • Bradford on Avon, Wiltshire, United Kingdom, BA15 1DQ
      • GSK Investigational Site
    • Trowbridge, Wiltshire, United Kingdom, BA14 8QA
      • GSK Investigational Site
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35294
      • GSK Investigational Site
    • Birmingham, Alabama, United States, 35215
      • GSK Investigational Site
    • Mobile, Alabama, United States, 36608
      • GSK Investigational Site
    • Ozark, Alabama, United States, 36360
      • GSK Investigational Site
    • Tallassee, Alabama, United States, 36078
      • GSK Investigational Site
  • Arizona
    • Chandler, Arizona, United States, 85224
      • GSK Investigational Site
    • Phoenix, Arizona, United States, 85023
      • GSK Investigational Site
    • Phoenix, Arizona, United States, 85012
      • GSK Investigational Site
    • Tucson, Arizona, United States, 85723
      • GSK Investigational Site
  • California
    • Fresno, California, United States, 93710
      • GSK Investigational Site
    • Fresno, California, United States, 93726
      • GSK Investigational Site
    • Long Beach, California, United States, 90808
      • GSK Investigational Site
    • Monterey Park, California, United States, 91754
      • GSK Investigational Site
    • National City, California, United States, 91950
      • GSK Investigational Site
    • San Diego, California, United States, 92117
      • GSK Investigational Site
    • San Diego, California, United States, 92128
      • GSK Investigational Site
    • Torrance, California, United States, 90502
      • GSK Investigational Site
    • Torrance, California, United States, 90505
      • GSK Investigational Site
    • Van Nuys, California, United States, 91405
      • GSK Investigational Site
  • Colorado
    • Boulder, Colorado, United States, 80304
      • GSK Investigational Site
    • Thornton, Colorado, United States, 80233
      • GSK Investigational Site
  • Connecticut
    • Hartford, Connecticut, United States, 06105
      • GSK Investigational Site
  • Florida
    • Clearwater, Florida, United States, 33765
      • GSK Investigational Site
    • Cocoa, Florida, United States, 32927
      • GSK Investigational Site
    • DeLand, Florida, United States, 32720
      • GSK Investigational Site
    • Fort Lauderdale, Florida, United States, 33316
      • GSK Investigational Site
    • Kissimmee, Florida, United States, 34741
      • GSK Investigational Site
    • Miami, Florida, United States, 33183
      • GSK Investigational Site
    • Pensacola, Florida, United States, 32503
      • GSK Investigational Site
    • Saint Petersburg, Florida, United States, 33707
      • GSK Investigational Site
    • Tampa, Florida, United States, 33603
      • GSK Investigational Site
    • Winter Park, Florida, United States, 32789
      • GSK Investigational Site
  • Georgia
    • Gainesville, Georgia, United States
      • GSK Investigational Site
    • Martinez, Georgia, United States, 30907
      • GSK Investigational Site
    • Riverdale, Georgia, United States, 30274
      • GSK Investigational Site
  • Idaho
    • Coeur d'Alene, Idaho, United States, 83814
      • GSK Investigational Site
  • Illinois
    • Aurora, Illinois, United States, 60504
      • GSK Investigational Site
    • Elk Grove Village, Illinois, United States, 60007
      • GSK Investigational Site
  • Indiana
    • Evansville, Indiana, United States, 47714
      • GSK Investigational Site
    • Evansville, Indiana, United States, 47713
      • GSK Investigational Site
  • Iowa
    • Council Bluffs, Iowa, United States, 51503
      • GSK Investigational Site
  • Kansas
    • Olathe, Kansas, United States, 66061
      • GSK Investigational Site
    • Topeka, Kansas, United States, 66606
      • GSK Investigational Site
  • Kentucky
    • Hazard, Kentucky, United States, 41701
      • GSK Investigational Site
    • Madisonville, Kentucky, United States, 42431
      • GSK Investigational Site
  • Massachusetts
    • Brockton, Massachusetts, United States, 02301
      • GSK Investigational Site
    • Fall River, Massachusetts, United States, 02720
      • GSK Investigational Site
    • Pittsfield, Massachusetts, United States, 01201
      • GSK Investigational Site
  • Michigan
    • Cadillac, Michigan, United States, 49601
      • GSK Investigational Site
  • Minnesota
    • Edina, Minnesota, United States, 55438
      • GSK Investigational Site
    • Fridley, Minnesota, United States, 55432
      • GSK Investigational Site
  • Missouri
    • Columbia, Missouri, United States, 65212
      • GSK Investigational Site
    • Saint Louis, Missouri, United States, 63141
      • GSK Investigational Site
    • Saint Louis, Missouri, United States, 63143
      • GSK Investigational Site
    • Springfield, Missouri, United States, 65803
      • GSK Investigational Site
  • Nebraska
    • Lincoln, Nebraska, United States, 68506
      • GSK Investigational Site
    • Omaha, Nebraska, United States, 68134
      • GSK Investigational Site
    • Papillion, Nebraska, United States, 68046
      • GSK Investigational Site
  • Nevada
    • Las Vegas, Nevada, United States, 89106
      • GSK Investigational Site
  • New Jersey
    • Cherry Hill, New Jersey, United States, 08003
      • GSK Investigational Site
    • Summit, New Jersey, United States, 07091
      • GSK Investigational Site
  • New York
    • Albany, New York, United States, 12205
      • GSK Investigational Site
    • North Syracuse, New York, United States, 13212
      • GSK Investigational Site
  • North Carolina
    • Asheville, North Carolina, United States, 28803
      • GSK Investigational Site
    • Burlington, North Carolina, United States, 27215
      • GSK Investigational Site
    • Charlotte, North Carolina, United States, 28207
      • GSK Investigational Site
    • Statesville, North Carolina, United States, 28625
      • GSK Investigational Site
    • Wilmington, North Carolina, United States, 28401
      • GSK Investigational Site
  • Ohio
    • Centerville, Ohio, United States, 45459
      • GSK Investigational Site
    • Toledo, Ohio, United States, 43614
      • GSK Investigational Site
  • Oregon
    • Portland, Oregon, United States, 97220
      • GSK Investigational Site
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19140
      • GSK Investigational Site
  • South Carolina
    • Charleston, South Carolina, United States, 29406
      • GSK Investigational Site
    • Columbia, South Carolina, United States, 29201
      • GSK Investigational Site
    • Easley, South Carolina, United States, 29640
      • GSK Investigational Site
    • Greenville, South Carolina, United States, 29615
      • GSK Investigational Site
    • Murrells Inlet, South Carolina, United States, 29576
      • GSK Investigational Site
    • Pelzer, South Carolina, United States, 29669
      • GSK Investigational Site
    • Spartanburg, South Carolina, United States, 29303
      • GSK Investigational Site
  • Tennessee
    • Nashville, Tennessee, United States, 37232
      • GSK Investigational Site
  • Texas
    • Corsicana, Texas, United States, 75110
      • GSK Investigational Site
    • Dallas, Texas, United States, 75231
      • GSK Investigational Site
    • Houston, Texas, United States, 77030
      • GSK Investigational Site
    • New Braunfels, Texas, United States, 78130
      • GSK Investigational Site
    • San Antonio, Texas, United States, 78229
      • GSK Investigational Site
    • Wichita Falls, Texas, United States, 76309
      • GSK Investigational Site
  • Virginia
    • Newport News, Virginia, United States, 23606
      • GSK Investigational Site
    • Richmond, Virginia, United States, 23249
      • GSK Investigational Site
  • Wisconsin
    • Madison, Wisconsin, United States, 53715
      • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Type of subject: outpatient
• Informed consent: Subjects must give their signed and dated written informed consent to participate.
• Gender: Male or female subjects A female is eligible to enter and participate in the study if she is of: Non-child bearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g., age appropriate, history of vasomotor symptoms. However in questionable cases, a blood sample with FSH > 40MIU/ml and estradiol <40pg/ml (<140 pmol/L) is confirmatory. OR

Child bearing potential, has a negative pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly (i.e., in accordance with the approved product label and the instructions of the physician for the duration of the study - screening to follow-up contact):

• Complete abstinence from intercourse from screening until the Follow-Up Phone Contact; or
• Male partner is sterile (vasectomy with documentation of azoospermia) prior to female subject entry into the study, and this male partner is the sole partner for that subject; or
• Implants of levonorgestral inserted for at least 1 month prior to the study medication administration but not beyond the third successive year following insertion; or
• Injectable progestogen administered for at least 1 month prior to study medication administration and administered until the Follow-Up Phone Contact; or
• Oral contraceptive (combined or progestogen only) administered for at least one monthly cycle prior to study medication administration; or
• Double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent (foam/gel/film/cream/suppository); or
• An intrauterine device (IUD), inserted by a qualified physician, with published data showing that the highest expected failure rate is less than 1% per year; or
• Estrogenic vaginal ring; or

• Percutaneous contraceptive patches

  • Age: ≥40 years of age at Screening (Visit 1)
  • COPD diagnosis: Subjects with a clinical history of COPD in accordance with the following definition by the American Thoracic Society/European Respiratory Society [Celli, 2004]: COPD is a preventable and treatable disease characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Although COPD affects the lungs, it also produces significant systemic consequences.
  • Tobacco use: Subjects with a current or prior history of ≥10 pack-years of cigarette smoking at Screening (Visit 1). Former smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Note: Pipe and/or cigar use cannot be used to calculate pack-year history. Number of pack years = (number of cigarettes per day/20) x number of years smoked
  • Severity of Disease:
• Subject with a measured post-albuterol/salbutamol FEV1/FVC ratio of ≤0.70 at Screening (Visit 1)

• Subjects with a measured post-albuterol/salbutamol FEV1 <70% of predicted normal values calculated (via centralized vendor equipment) using NHANES III reference equations [Hankinson, 1999] at Screening (Visit 1). Post-bronchodilator spirometry will be performed approximately 10-15 minutes after the subject has self-administered 4 inhalations (i.e., total 400mcg) of albuterol/salbutamol via an MDI with a valved-holding chamber. The study provided central spirometry equipment will calculate the FEV1/FVC ratio and FEV1 percent predicted values.

  • History of Exacerbations: A documented history (e.g., medical record verification) of at least one COPD exacerbation in the 12 months prior to Visit 1 that required either oral corticosteroids, antibiotics and/or hospitalization. Prior use of antibiotics alone does not qualify as an exacerbation history unless the use was associated with treatment of worsening symptoms of COPD, such as increased dyspnea, sputum volume, or sputum purulence (color). Subject verbal reports are not acceptable.

Exclusion Criteria:

Subjects meeting any of the following criteria must not be enrolled in the study:

• Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
• Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD)
• α1-antitrypsin deficiency: Subjects with α1-antitrypsin deficiency as the underlying cause of COPD
• Other respiratory disorders: Subjects with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases
• Lung resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening (Visit 1)
• Chest X-ray (or CT scan): Subjects with a chest X-ray (or CT scan) that reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD. A chest X-ray must be taken at Screening (Visit 1) if a chest X-ray or CT scan is not available within 6 months prior to Visit 1. For sites in Germany, if a chest X-ray (or CT scan) is not available in the 6 months preceding Screening (Visit 1), the subject will not be eligible for the study.
• Risk Factors for Pneumonia: immune suppression (HIV, Lupus, etc) or other risk for pneumonia (e.g. neurological disorders affecting control of the upper airway, such as Parkinson's, Myasthenia Gravis, etc).
• A moderate and severe COPD exacerbation that has not resolved at least 14 days prior to Visit 1 and at least 30 days following the last dose of oral corticosteroids (if applicable).
• Pneumonia and/or moderate and severe COPD exacerbation at Visit 1 Note: Subjects who experience a pneumonia and/or exacerbation at Screening (Visit 1) must be not continue in the study, but may be re-screened at a later time provided the pneumonia and/or COPD exacerbation has resolved prior to the re-screening visit. At the Re-screening Visit, the chest x-ray should confirm resolution of pneumonia. The Re-screening Visit must be conducted at least ≥ 14 days following the resolution date of the exacerbation and/or pneumonia and at least 30 days following the last dose of oral corticosteroids (if applicable).
• Other diseases/abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular (i.e., pacemaker), neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or haematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
• Peptic Ulcer disease: Subjects with clinically significant peptic ulcer disease that is uncontrolled.
• Hypertension: Subjects with clinically significant hypertension that is uncontrolled.
• Cancer: Subjects with carcinoma that has not been in complete remission for at least 5 years. Carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded if the subject has been considered cured within 5 years since diagnosis.
• Drug/food allergy: Subjects with a history of hypersensitivity to any of the study medications (e.g., beta-agonists, corticosteroid) or components of the inhalation powder (e.g., lactose, magnesium stearate). In addition, subjects with a history of severe milk protein allergy that, in the opinion of the study physician, contraindicates the subject's participation will also be excluded.
• Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years
• Medication prior to spirometry: Subjects who are medically unable to withhold their albuterol/salbutamol and/or their ipratropium for the 4-hour period required prior to spirometry testing at each study visit.
• Additional medication: Unable to stop using certain medications such as bronchodilators and corticosteroids for the protocol-specified times prior to Visit 1 (the Investigator will discuss the specific medications)
• Oxygen therapy: Subjects receiving treatment with long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for greater than 12 hours a day. Oxygen prn use (i.e., ≤12 hours per day) is not exclusionary.
• Sleep apnea: Subjects with clinically significant sleep apnea who require use of continuous positive airway pressure (CPAP) device or non-invasive positive pressure ventilation (NIPPV) device.
• Pulmonary rehabilitation: Subjects who have participated in the acute phase of a Pulmonary Rehabilitation Program within 4 weeks prior to Screening (Visit 1) or who will enter the acute phase of a Pulmonary Rehabilitation Program during the study. Subjects who are in the maintenance phase of a Pulmonary Rehabilitation Program are not excluded.
• Non-compliance: Subjects at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits.
• Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study.
• Prior use of study medication/other investigational drugs: Subjects who have previously been randomized to treatment with GW642444 Inhalation Powder in the B2C111045 study, randomized to treatment in the HZC111348 study or have participated in the HZC112207, HZC102871, HZC102970, or HZC110946 studies. Subjects who have received an investigational drug within 30 days of entry into this study (Screening), or within 5 drug half-lives of the investigational drug, whichever is longer.
• Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or immediate family members of the aforementioned are excluded from participating in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: FF/GW642444 Inhalation Powder 100/25 mcg QD; Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)	Drug: FF/GW642444 Inhalation Powder; Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
Experimental: FF/GW642444 Inhalation Powder 50mcg/25mcg QD; Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)	Drug: FF/GW642444 Inhalation Powder; Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
Experimental: FF/GW642444 Inhalation Powder 200/25 mcg QD; Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)	Drug: FF/GW642444 Inhalation Powder; Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
Experimental: GW642444 25mcg QD; Long Acting Beta Agonist(LABA)	Drug: GW642444 Inhalation Powder; Long Acting Beta Agonist(LABA) Inhalation Powder

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Annual Rate of Moderate and Severe COPD Exacerbations Expressed as Least Square Mean	The annual rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations during the treatment (trt) period (per participant [par.] per year) was assessed. An exacerbation of COPD, is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence [color]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptoms (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. The COPD exacerbation was categorized as mild, moderate and severe by the investigator. Mild: worsening symptoms of COPD that were self-managed by the par. without the use of oral corticosteroids or antibiotics; Moderate: worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics; Severe: worsening symptoms of COPD that required treatment with in-patient hospitalization.	From the start of the double blind study medication until Visit 11 (Week 52)/Early Withdrawal

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to First Occurrence of Moderate or Severe COPD Exacerbation	Time to first occurrence analyzed by using a Cox proportional hazards model with covariates of treatment, smoking status at screening (stratum), baseline disease severity (pre-dose Day 1 % predicted FEV1) and centre grouping. An exacerbation of COPD is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence [color]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptoms (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. A moderate exacerbation is defined as worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics. A severe exacerbation is defined as worsening symptoms of COPD that required treatment with in-patient hospitalization. The number of participants with a moderate or severe COPD exacerbation while on treatment are presented.	From the start of the double blind study medication until Visit 11 (Week 52)/Early Withdrawal
Annual Rate of Exacerbations Requiring Systemic/Oral Corticosteroids Expressed as Least Square Mean	The annual rate of COPD exacerbations during the treatment period (per participant per year) that required systemic/oral corticosteroids was assessed. An exacerbation of COPD is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence [color]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptom (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. The COPD exacerbation was categorized as mild, moderate, and severe by the investigator. Mild: worsening symptoms of COPD that were self-managed by the participant. Mild exacerbations were not associated with the use of oral corticosteroids or antibiotics. Moderate: worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics. Severe: worsening symptoms of COPD that required treatment with in-patient hospitalization.	From the start of the double blind study medication until Visit 11 (Week 52)/Early Withdrawal
Change From Baseline in Trough FEV1 at Week 52 (Visit 11)	Pulmonary function was measured by forced expiratory volume in one second (FEV1). Trough FEV1 was defined as the 24-hour post-dose FEV1 assessment, which was obtained at each visit. Analysis performed using a repeated measures model with covariates of treatment, smoking status at Screening (stratum), baseline (pre-dose Day 1), centre grouping, Week, Week by Baseline, and Week by treatment interactions.	Baseline to Visit 11 (Week 52)/Early Withdrawal

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Publications and helpful links

General Publications

• Largajolli A, Beerahee M, Yang S. Bayesian approach to investigate a two-state mixed model of COPD exacerbations. J Pharmacokinet Pharmacodyn. 2019 Aug;46(4):371-384. doi: 10.1007/s10928-019-09643-6. Epub 2019 Jun 13. Erratum In: J Pharmacokinet Pharmacodyn. 2019 Dec;46(6):627.
• Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013 May;1(3):210-23. doi: 10.1016/S2213-2600(13)70040-7. Epub 2013 Apr 12. Erratum In: Lancet Respir Med. 2013 May;1(3):186.
• Hinds DR, DiSantostefano RL, Le HV, Pascoe S. Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis. BMJ Open. 2016 Jun 1;6(6):e010099. doi: 10.1136/bmjopen-2015-010099.
• Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Lettis S, Calverley PM. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015 Jan;12(1):27-34. doi: 10.1513/AnnalsATS.201409-413OC.
• Svedsater H, Dale P, Garrill K, Walker R, Woepse MW. Qualitative assessment of attributes and ease of use of the ELLIPTA dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med. 2013 Dec 7;13:72. doi: 10.1186/1471-2466-13-72.

Helpful Links

• Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.

Study record dates

Study Major Dates

• Study Start: September 25, 2009
• Primary Completion (Actual): October 1, 2011
• Study Completion (Actual): October 17, 2011

Study Registration Dates

• First Submitted: November 19, 2009
• First Submitted That Met QC Criteria: November 19, 2009
• First Posted (Estimate): November 23, 2009

Study Record Updates

• Last Update Posted (Actual): August 31, 2018
• Last Update Submitted That Met QC Criteria: August 2, 2018
• Last Verified: August 1, 2018

More Information

Terms related to this study

• Keywords: Safety; COPD; Efficacy; FEV1
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive
• Other Study ID Numbers: 102970

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes
• IPD Plan Description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Study Data/Documents

1. Annotated Case Report Form
   Information identifier: 102970
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
2. Study Protocol
   Information identifier: 102970
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
3. Dataset Specification
   Information identifier: 102970
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
4. Clinical Study Report
   Information identifier: 102970
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
5. Individual Participant Data Set
   Information identifier: 102970
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
6. Informed Consent Form
   Information identifier: 102970
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
7. Statistical Analysis Plan
   Information identifier: 102970
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register